Key Dates

Related Announcements

• March 19, 2024 - Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK (R21 Clinical Trial Not Allowed). See NOFO PAR-24-162.
• March 6, 2024 - Model Continuums of Care Initiative (MCCI) to Advance Health Equity and End Health Disparities Among Women and Girls in Racial/Ethnic Minority and Other Underserved Communities (U34 Clinical Trials Required). See NOFO RFA-AA-24-006.
• March 1, 2024 - Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional). See NOFO PAS-24-163
• January 26, 2023 - Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32). See NOFO PA-23-048.
• June 9, 2022 - Research Opportunities for New and “At-Risk” Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional). See NOFO PAR-22-181.
• January 10, 2022 - Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed). See NOFO PAR-22-060
• September 8, 2021 – Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed). See NOFO PAR-21-252.
• September 8, 2021 – Emerging Global Leader Award (K43 Independent Clinical Trial Required). See NOFO PAR-21-251.
• August 17, 2021 - Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Clinical Trial Required). See NOFO PAR-21-272.
• August 17, 2021 - Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed). See NOFO PAR-21-271.
• May 19, 2021 - Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 Clinical Trial Not Allowed). See NOFO PAR-21-155
• February 1, 2024 - NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required). See NOFO PAR-24-124.
• February 1, 2024 – NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required). See NOFO PAR-24-116.
• January 22, 2024 - International Research Scientist Development Award (IRSDA) (K01) Independent Clinical Trial Not Allowed. See NOFO PAR-24-113.
• January 22, 2024 - International Research Scientist Development Award (IRSDA) (K01) Independent Clinical Trial Required. See NOFO PAR-24-114.
• January 20, 2024 - Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required). See NOFO PAR-24-084.
• December 21, 2023 - Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required). See NOFO PAR-24-086.
• December 21, 2023 - NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required). See NOFO PAR-24-083.
• September 12, 2023 - Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31-Diversity). See NOFO PA-23-271.
• September 7, 2023 - Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30). See NOFO PA-23-261.
• September 7, 2023 - Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32). See NOFO PA-23-262.
• August 17, 2023 - Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31). See NOFO PA-23-272.
• August 16, 2023 - Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions with NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30). See NOFO PA-23-260.
• May 12, 2023 – HIV Prevention and Alcohol (R01 Clinical Trials Optional). See NOFO PAS-23-173.
• May 12, 2023 – HIV Prevention and Alcohol (R34 Clinical Trials Optional) See NOFO PAS-23-172.
• May 10, 2023 – HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional). See NOFO PAR-23-191.
• May 10, 2023 – HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R01 Clinical Trial Optional). See NOFO PAR-23-190.
• March 17, 2023 - Research with Activities Related to Diversity (ReWARD) (R01 Clinical Trial Optional). See NOFO PAR-23-122.
• January 11, 2023 - Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional). See NOFO PAR-23-062.
• January 11, 2023 - Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional). See NOFO PAR-23-061.
• January 11, 2023 - Formative and Pilot Intervention Research to Optimize HIV Prevention and Care Continuum Outcomes (R34 Clinical Trial Optional). See NOFO PAR-23-060.
• August 25, 2022 - Catalyst Award for Early-Stage Investigators (ESIs) Pursuing Research on HIV Comorbidities, Coinfections, and Complications (DP1- Clinical Trial Optional). See NOFO PAR-23-024.
• May 10, 2022 – Dissemination and Implementation Research in Health (R01 Clinical Trial Optional). See NOFO PAR-22-105.
• May 10, 2022 – Dissemination and Implementation Research in Health (R21 Clinical Trial Optional). See NOFO PAR-22-109.
• May 25, 2022 - Mental Health Research Dissertation Grant to Enhance Workforce Diversity (R36 Independent Clinical Trial Not Allowed). See NOFO PAR-22-172.
• February 9, 2022 - Global Brain and Nervous System Disorders Research Across the Lifespan (R21 Clinical Trial Optional). See NOFO PAR-22-098.
• February 8, 2022 - Global Brain and Nervous System Disorders Research Across the Lifespan (R01 Clinical Trial Optional). See NOFO PAR-22-097.
• August 20, 2021 - Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional). See NOFO PAR-21-313.  
• August 17, 2021 - Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Basic Experimental Studies with Humans Required (BESH)). See NOFO PAR-21-273.
• May 10, 2021 - Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional). See NOFO PA-21-219.
• April 23, 2021 - NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Independent Clinical Trial Not Allowed). See NOFO PAR-21-234.
• April 8, 2021 - NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Clinical Trial Required). See NOFO PAR-21-153.
• October 15, 2020 – NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed). See NOFO PAR-21-032.
• May 12, 2020 – Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed). See NOFO PA-20-205.
• May 12, 2020 – Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required). See NOFO PA-20-206.
• May 12, 2020 – Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed). See NOFO PA-20-203.
• May 12, 2020 – Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required). See NOFO PA-20-202.
• May 12, 2020 – Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Basic Experimental Studies with Humans Required). See NOFO PA-20-201.
• May 11, 2020 – Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Basic Experimental Studies with Humans Required). See NOFO PA-20-204.
• May 7, 2020 – NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed). See NOFO PA-20-200.
• May 7, 2020 – NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed). See NOFO PA-20-195.
• May 7, 2020 – NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required). See NOFO PA-20-194.
• May 7, 2020 – NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required). See NOFO PA-20-196.
• May 7, 2020 - Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Not Allowed). See NOFO PA-20-199.
• May 7, 2020 - Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Required). See NOFO PA-20-197.
• May 7, 2020 - Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimental Studies with Humans Required). See NOFO PA-20-198.
• May 6, 2020 – Mentored Research Scientist Development Award (Parent K01 – Independent Clinical Trial Not Allowed). See NOFO PA-20-190.
• May 6, 2020 – Mentored Research Scientist Development Award (Parent K01 – Independent Clinical Trial Required). See NOFO PA-20-176.
• May 6, 2020 – Midcareer Investigator Award in Patient-Oriented Research (Parent K24 – Independent Basic Experimental Studies with Humans Required). See NOFO PA-20-192.
• May 6, 2020 – Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required). See NOFO PA-20-193.
• May 6, 2020 – Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Not Allowed). See NOFO PA-20-186.
• May 6, 2020 – Mentored Research Scientist Development Award (Parent K01 Independent Basic Experimental Studies with Humans Required). See NOFO PA-20-191
• May 5, 2020 – NIH Research Project Grant (Parent R01 Clinical Trial Required). See NOFO PA-20-183.
• May 5, 2020 – NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed). See NOFO PA-20-185.
• May 5, 2020 – NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required). See NOFO PA-20-184.
• May 5, 2020 - NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required). See NOFO PA-20-187.
• May 5, 2020 - NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed). See NOFO PA-20-188.
• May 5, 2020 - NIH Pathway to Independence Award (Parent K99/R00 Independent Basic Experimental Studies with Humans Required). See NOFO PA-20-189.
• April 23, 2020 – Independent Scientist Award (Parent K02 – Independent Clinical Trial Not Allowed). See NOFO PA-20-174.
• April 23, 2020 – Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Humans Required). See NOFO PA-20-173.
• April 23, 2020 – Independent Scientist Award (Parent K02 – Independent Clinical Trial Required). See NOFO PA-20-171.

Issued by

Office of Research on Women's Health (ORWH)

Office of AIDS Research (OAR)

National Institute on Aging (NIA)

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

National Institute of Allergy and Infectious Diseases (NIAID)

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

National Institute on Drug Abuse (NIDA)

National Institute of Mental Health (NIMH)

National Institute of Neurological Disorders and Stroke (NINDS)

National Institute on Minority Health and Health Disparities (NIMHD)

Fogarty International Center (FIC)

National Center for Complementary and Integrative Health (NCCIH)

National Cancer Institute (NCI)

All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.

Office of Behavioral and Social Sciences Research (OBSSR)

Sexual and Gender Minority Research Office (SGMRO)

Purpose

The NIH Office of Research on Women’s Health (ORWH) and Office of AIDS Research (OAR), in partnership with our Institute, Center, and Office (ICO) partners are issuing this Notice to highlight interest in receiving HIV research and training grant applications that explicitly and intersectionally center the health needs of cisgender women and girls, and gender-diverse people.

Despite tremendous scientific advances that have translated to substantial progress in confronting the HIV epidemic, women – and particularly women of color, young women and girls, and transgender women – and gender-diverse individuals remain disproportionately affected by HIV. An intersectional, equity-informed, data-driven approach is essential to advance HIV research and clinical care for all women with or impacted by HIV across their lifespan and to end the HIV pandemic (Barr et al, 2024).

Background

According to UNAIDS, women and girls accounted for more than half (53%; 20.7 million) of the 39 million people with HIV and 46% of new acquisitions in 2022 with approximately 4,000 adolescent girls and women (AGYW) aged 15-24 years acquiring HIV on a weekly basis. Worldwide HIV prevalence among transgender women is approximately 20% and transgender women experience a 14-fold higher chance of acquiring HIV (Stutterheim 2021). Although 81% of the 1.3 million pregnant women with HIV receive antiretroviral therapy to prevent perinatal transmission, breast/chest-feeding is complicated by HIV status. The WHO estimates 1.22% of maternal deaths world-wide are HIV-related and pregnancy in women with HIV is complicated by an increased association with comorbidities resulting in a 2-10-fold increased chance of mortality (Calvert et al, 2013; Trends in maternal mortality 2000 to 2017: estimates by WHO, UNICEF, UNFPA, World Bank Group and the United Nations Population Division)

In the United States and dependent areas, data from the Centers for Disease Control and Prevention indicate that over 250,000 women were living with HIV and more than 5,000 women newly acquired HIV in 2020. Black and African American women accounted for 54% of new diagnoses among females despite only comprising 13% of the female population. An estimated 44% of Black and African American transgender women and 26% of Latinx transgender women in the U.S. are living with HIV (Becasen et al., 2019; UNAIDS, 2022). New HIV acquisitions were highest among women aged 25 to 34 years. Approximately 54% of women with HIV in the US are over the age of 50 and CDC analyses report that HIV acquisition among women 55 and older increased 7% from 2015-2019 further demonstrating that women with HIV are aging, and aging women remain vulnerable to HIV.

Insufficient consideration of sex, gender, and their intersections in health as well as limited inclusion of women and gender diverse people in health research reduces the availability and accessibility of safe and effective HIV prevention, treatment, and cure modalities (Curno et al., 2016; Pepperrell et al, 2020; NASEM, 2022). Prioritizing the inclusion of diverse populations of women in prevention, therapeutic, and cure-related research is an essential component of ending the HIV epidemic.

Informed by responses received to a Request for Information (NIH Request for Information (RFI) on Research Opportunities Related to HIV and Women’s Health (NOT-OD-24-011)) and analyses of the NIH HIV research portfolio, this Notice of Special Interest highlights key opportunities of high interest at the intersection of HIV and women’s health.

Institute and Center-specific areas of high interest for this NOSI are listed below. A comprehensive list of NIH-wide research opportunities to center the health of women across the HIV research continuum can be found at NOT-OD-24-117. Applicants are strongly encouraged to discuss proposed submissions for this initiative with the scientific contact for the proposed Institute or Center prior to submission to ensure alignment with Institute or Center mission areas and priorities for this initiative.

NIH Office of Research on Women’s Health (ORWH)

ORWH is part of the Office of the Director, NIH, and works with the 27 NIH Institutes and Centers to advance rigorous research of relevance to the health of women. ORWH does not award grants but co-funds women’s health-related applications and research projects that have received an award from one of the participating NIH Institutes and Centers (ICs) listed in the announcement. Applications seeking ORWH co-funding should ensure that the proposed work is aligned with at least one goal and objective outlined in the NIH-Wide Strategic Plan for Research on the Health of Women (https://www.nih.gov/women/strategicplan).

For this announcement, ORWH welcomes intersectional research projects that address topics of relevance to cisgender and transgender women and gender-diverse people.

NIH Office of AIDS Research (OAR)

OAR is part of the Office of the Director, NIH, and works in partnership with the NIH Institutes, Centers, and Offices in coordination of the NIH HIV Research Program and to ensure that HIV/AIDS research is aligned with the NIH Strategic Plan for HIV and HIV Related Research (https://oar.nih.gov/hiv-policy-and-research/strategic-plan). The OAR does not award grants but co-funds HIV-related applications and research projects that have received an award from one of the participating NIH Institutes and Centers (ICs) listed in the announcement. Projects must align with at least one of the strategic goals and objectives outlined in the NIH Strategic Plan for HIV and HIV Related Research. Please contact the relevant ICO Scientific/Research Contact(s) listed with any questions regarding the ICO research priorities and funding.

National Cancer Institute (NCI)

The National Cancer Institute (NCI) encourages research that advances our understanding of the risks, development, progression, diagnosis, and treatment of cancer.  People with HIV are at higher risk for certain cancers than the general population with many factors thought to contribute to increased risk of these HIV-associated malignancies, including chronic immunosuppression, chronic inflammation and “accelerated aging”.  Through this NOSI, NCI will support research that falls within the NCI’s mission and specifically focuses on cancers observed in women (W) and trans and gender diverse (TGD) people with HIV. NCI will support research efforts that identify specific contributions of HIV infection on (a) the pathogenesis of co-infecting oncogenic pathogens, (b) the development of virally-associated cancers and associated disease sequelae, (c) investigations of modifiable factors/environmental exposures in W/TGD people at risk for HIV-associated cancers, and (d) the clinical outcomes of such cancers in W/TGD people with HIV. Ultimately, such efforts could guide development of targeted cancer screening approaches and therapies optimized for W/TGD people with HIV.

While not an exhaustive list, NCI aims to promote research projects addressing the following in W/TGD people with HIV:

• Identifying specific contributions of HIV infection and its potential interaction with other pathogens toward the development and pathogenesis of cancer;
• Research that provides clinical information on cancer screening, prevention, treatment, and outcomes;
• Research that identifies biological sex and gender identity differences across the cancer research and care continuum;
• Identification of ways to address disparities based on biological sex and gender identity to better screen, prevent, diagnose, and treat cancer;
• Research to understand how aging in the presence of chronic HIV infection affects the risk, spectrum, and biology of cancer;
• Research that examines social and behavioral factors that may impact quality of life in women and TGD people with HIV and cancer.

National Institute on Aging (NIA)

NIA supports a diverse portfolio of research aimed at promoting healthy aging among older adults living with HIV, including aging as a process and its consequences, aging as a complex phenomenon, influences upon aging and rate of aging, age-related diseases, conditions, and disability, and aging in societal, economic, and environmental contexts.

For this announcement, NIA is seeking research projects that address the intersection of HIV, aging, and women’s health. As the number of women aging with HIV continues to increase, more research is needed to understand the impact of sex differences on accelerated aging and conditions associated with aging, including physical and cognitive impairment, menopause, multimorbidity and polypharmacy in this population.

Areas of interest to NIA include but are not limited to:

• Studies that consider sex differences to understand the effects of HIV on the hallmarks of aging and the systemic coordination of cellular and physiological processes related to aging.
• Research that explores the relationship between HIV and accelerated reproductive aging.
• Studies that examine the effectiveness of interventions to reduce aging-related complications in women living with HIV.
• Research that explores the effects of HIV and ART on the aging process in women with HIV.
• Studies that investigate the interaction of HIV, sex hormones and onset and progression of neurodegeneration and Alzheimer's disease and Alzheimer’s disease-related dementias (AD/ADRD) at the molecular and cellular levels in women living with HIV compared to men living with HIV.
• Research to improve clinical outcomes and prevent premature aging, including neurocognitive decline (HIV-associated Neurocognitive Decline (HAND)/HIV-Associated Brain Injury (HABI)) and AD/ADRD in women living with HIV compared to men living with HIV.
• Studies that examine gender-based violence as a cause and consequence of HIV infection and its effects on clinical outcomes.
• Research that investigates health issues and systemic challenges faced by women in caregiving roles, as well as those aging with HIV, highlighting perspectives of both caregivers and care partners.
• Research aimed at addressing disparities in healthcare access and enhancing the quality of care provided for partnered and unpartnered women with HIV.

National Institute of Allergy and Infectious Diseases (NIAID)

NIAID supports research programs that focus on HIV and other health outcomes in women to inform and enable more targeted and effective HIV prevention, care, and treatment.  Although not intended to be an exhaustive list, NIAID is interested in receiving hypothesis-driven research applications (including mentorship, training, and career development mechanisms) through this NOSI that can address current scientific gaps in research specific to women that will:

• Elucidate sex- and/or gender-based differences in host and HIV-specific mechanisms related to transmission, susceptibility, host-pathogen interactions, innate and adaptive immune responses to infection and vaccination including adverse events; characterization of latency, persistence and viral reservoirs; treatment and/or prevention clinical outcomes;
• Accelerate development of HIV treatment and prevention modalities, including ultra-long-acting strategies for associated co-infections and/or coupled to contraception and/or hormone replacement therapy (HRT) in women across the lifespan;
• Improve understanding of the impact of menopause, pregnancy, or breast-feeding on disease pathogenesis and/or HIV treatment and prevention outcomes;
• Develop novel pre-clinical models (in-vitro, in-vivo and in-silico) to understand sex- and/or gender-based differences that can enhance basic, translational and clinical research focused on prevention and/or treatment of HIV and associated co-infections and/or contraception;
• Employ novel data science and analytic methods, epidemiology concepts, or enhanced dissemination and implementation methodologies that lead to better identification of vulnerabilities, or better inform end-user data collection in/around women’s preferences/usage of HIV prevention and treatment modalities across the lifespan.

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

The mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is to support research into the causes, treatment, and prevention of arthritis (and other rheumatic) and musculoskeletal, and skin diseases. NIAMS is interested in studies encompassing basic, translational, and/or clinical research in biological, genomic, psychological, social, and behavioral realms on HIV and women’s health, as long as they fall within NIAMS' mission areas, and are focused on conditions that have been underexplored or more prevalent among women with HIV/AIDS.

Examples of HIV/AIDS related health issues that fall within NIAMS' scope include musculoskeletal discomfort, muscle ailments (such as sarcopenia, cachexia, and muscular dystrophy), cartilage deterioration (such as osteoarthritis), bone disorders (such as osteoporosis and osteopenia), bone fractures, various forms of arthritis and rheumatic diseases (such as systemic lupus erythematosus, reactive arthritis, and psoriatic arthritis, and septic arthritis), as well as dermatological manifestations.

Applicants are encouraged to discuss potential applications with the appropriate NIAMS program director.

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is interested in supporting women and HIV research on topics relevant to NICHD's populations of interest, including children; adolescents; pregnant and/or lactating individuals; and persons with intellectual, developmental, and/or physical disabilities across the lifespan. NICHD is particularly interested in research that relates to the Institute’s high-priority research areas: see https://www.nichd.nih.gov/grants-contracts/research-areas/priorities for current research priorities, and https://www.nichd.nih.gov/about/org/strategicplan regarding research themes for the Institute. Please note that applications assigned to NICHD that address the mission and priorities of other Institutes that are not participating in this NOSI will not be prioritized for funding by NICHD.

Specific topics of interest to the NICHD include, but are not limited to, women and HIV research on the following:

• Studies to increase the use of multilevel interventions to improve health and prevent HIV (e.g., feasible, acceptable, safe, and scalable strategies to increase uptake of and adherence to HIV prevention modalities), particularly in adolescents and young adults.
• Identifying and investigating adverse pregnancy and infant outcomes that may be associated with antiretroviral therapy in pregnancy to improve understanding of how such exposures contribute to maternal morbidity and mortality, stillbirth, preterm birth, and the long-term health of women and their children.
• Overlap of gynecologic disorders, including endometriosis and fibroids, with HIV/AIDS or PrEP. Intersections of interest include overlapping disease processes, crosstalk between diseases or therapeutics, or development of diagnostics for both HIV and gynecologic conditions.
• Prevalence, biological mechanisms, and clinical risk factors responsible for the development of gynecologic pain syndromes in those living with HIV and taking PrEP.
• Effects of HIV or ART/PreP use on menstruation, peri-menopause, and/or the menopausal transition.

National Institute on Drug Abuse (NIDA)

The National Institute of Drug Abuse (NIDA) is interested in supporting women and HIV research on topics relevant to NIDA's populations of interest, including children; adolescents; pregnant and/or lactating individuals; at risk for or living with substance use disorders across the lifespan. Substances of interest include opioids, fentanyl, nicotine, cocaine, methamphetamine, stimulants, xylazine, psychedelics, addictive prescription drugs, cannabinoids, or combinations of these substances. NIDA's strategic plan is available at https://nida.nih.gov/about-nida/2022-2026-strategic-plan/introduction. NIDA strongly encourages applicants to address one of the research priorities of NIDA HIV Research Program. NIDA’s HIV research priority areas are available at https://nida.nih.gov/about-nida/organization/offices/hiv-research-program-hrp/about-hiv-research-program.

Further, NIDA is interested in research designed to address the unique challenges experienced by cis- and gender-diverse women at risk for or living with HIV as well as research to enhance HIV prevention and service delivery efforts specific to these women. People with substance use and substance use disorder (SUD), particularly women of color and gender-diverse women, continue to experience gaps in the HIV care continuum, increased burden of comorbidities, and poor health outcomes. NIDA seeks applications for HIV prevention and services research that acknowledge and seek to address the intersection of race, ethnicity, social determinants of health, substance use, and HIV among women. NIDA is also interested in furthering our understanding of the unique risk and protective factors of cis gender and gender diverse women at risk for or living with HIV, specifically those who use substances. Research that can lead to innovative and targeted intervention and prevention strategies will be prioritized. Intersectional stigma, including substance use- and HIV-related stigmas and power dynamics/imbalances needs to be addressed to enhance HIV prevention and treatment efforts.

Areas of interest to NIDA include but are not limited to:

• Identifying and investigating adverse outcomes that may be associated with HIV, antiretroviral therapy and substance use in pregnancy to improve understanding of how such exposures contribute to maternal morbidity and mortality, and the long-term health of women;
• Effects of HIV, ART/PreP and addictive substance use on menstruation, peri-menopause, and/or the menopausal transition;
• Mechanistic research investigating complex morbidities, including psychiatric, neurologic, metabolic and other comorbidities occurring with SUD and HIV, and their manifestation and impact across reproductive and life stages of women;
• Research that leverages existing epidemiological data to address patterns and effects of substance use, including polysubstance use among cis- and gender-diverse women at risk for or living with HIV;
• Studies to develop and test multi-level, women-focused intervention approaches at the individual, patient-provider, family, community, and systems levels;
• Research to address social and structural determinants of health at the intersection of HIV and substance use among cis- and gender-diverse women at risk for or living with HIV;
• Projects that adapt, integrate, implement, and/or scale up evidence-based HIV prevention and treatment programs for cis- and gender-diverse women who use substances, with particular attention to intervention sustainability;
• Studies that address the intersection of substance use and HIV among cis- and gender diverse women in or recently discharged from the criminal legal system, including those in community corrections and diversion programs as well as those under social welfare supervision.

Applicants are strongly encouraged to engage stakeholders and potential end users of their research, including women with lived experience, in the development and implementation of the research study. Applicants should ensure that interventions and strategies being developed and tested in response to this NOSI are scalable, sustainable, and impact diverse populations, including those from NIH-designated populations that experience health disparities and other underserved groups.

Investigators are strongly encouraged to discuss their research plans with NIDA program staff prior to submitting their application.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIDDK encourages research on sex/gender differences, sexual and gender minority-related research and race/ethnic diversity, see NOT-DK-22-003.html. For example, NIDDK invites applications that address how sex and gender influence HIV comorbidities, co-infections, and complications within its mission.  Diseases and conditions within NIDDK’s mission include diabetes and other endocrine and metabolic diseases; gastrointestinal, liver, and pancreatic diseases, nutritional disorders, and obesity; and kidney, urologic, and/or hematologic diseases.  In addition, several tissues within NIDDK’s mission represent important HIV reservoirs. These include the gastrointestinal mucosa, the kidney, and adipose tissue. Gender and sex may influence reservoir dynamics differently across the lifespan and in different tissues. Therefore, NIDDK also invites projects that address HIV reservoirs in NIDDK-relevant anatomical sites and the impact of NIDDK-relevant processes on HIV reservoirs in women.  NIDDK has many research areas within its mission, but not all research related to relevant diseases will be appropriate for NIDDK. Applicants are strongly encouraged to contact NIDDK staff as soon as possible in the development of the application, so that NIDDK staff can help the applicant understand whether the proposed project is within the goals and mission of the Institute.

Areas of interest include but are not limited to:

• Pathophysiological pathways whereby sex or gender influence the development or progression of NIDDK-relevant comorbidities, co-infections, and complications in women with HIV.
• Interactions of sex and gender, HIV or its treatment, and physiological processes within NIDDK’s mission, such as metabolism, normal blood development, or gastrointestinal mucosal immune homeostasis.
• Cellular and molecular characterization of the influence of sex and gender on HIV reservoirs in the gastrointestinal mucosa, the kidney, or adipose tissue across the lifespan in women with HIV.
• The impact of health-impeding social determinants of health on development of NIDDK-relevant comorbidities, co-infections, and complications in women with HIV.
• The impact of health-impeding social determinants of health on viral reservoirs in tissues within the NIDDK’s mission.
• Effectiveness research on programs aiming to alleviate health-impeding social determinants of health to reduce NIDDK-related comorbidities, co-infections, and complications in women with HIV.

National Institute of Mental Health (NIMH)

The Division of AIDS Research (DAR) supports research to reduce the incidence of HIV worldwide and to decrease the burden of living with HIV. DAR-supported research encompasses a broad range of studies that includes basic and clinical neuroscience of HIV to understand and alleviate the consequences of HIV in the central nervous system (CNS), and basic and applied behavioral and social science to prevent HIV and limit morbidity and mortality among those living with HIV. DAR places a high priority on interdisciplinary research across multiple populations, including racial and ethnic minorities and sexual and gender minorities, over the lifespan.

Areas of research interest for NIMH include, but are not limited to:

• Studies to advance the development and testing of interventions to reduce the acquisition of HIV among women delivered beyond the individual level, by incorporating appropriate context into intervention development and testing.
• Research focused on choice of HIV prevention or treatment products for women that incorporates novel products as they become available.
• Research to develop (or model) strategies to increase HIV testing, ensure timely treatment initiation, and improve linkage to care for women.
• Research to develop and test interventions to improve HIV treatment outcomes for women through optimal treatment adherence and sustained engagement in care.
• Implementation science research to develop and test implementation strategies, optimize delivery of interventions, and scale up evidence-based interventions for women.
• Research focused on gaining mechanistic insights into distinctive phenotypes of cognitive impairments and CNS co-morbidities observed in women with HIV on ART.
• Research to better understand the impact of psychosocial and socioeconomic factors on CNS outcomes in women living with HIV on suppressive ART.
• Longitudinal studies of cognitive and mental health trajectories in women living with HIV on ART.
• Computational and mathematical modeling approaches using multiple existing population-level surveys and NIH-funded cohorts to improve HIV prevention and treatment that considers individual, community, social, and structural factors that influence women’s engagement in HIV testing, prevention, and care.
• Research focused on the prevention of HIV among adolescent girls and young women (AGYW) as well as improve the health and well-being of AGYW who are living with HIV that is tailored to their unique developmental context.
• Research focused on potential sex based differences in HIV CNS persistence and the implications in the development of potential HIV-1 curative strategies.
• Research focused on potential sex based differences in HIV CNS persistence and the implications in the development of potential HIV-1 curative strategies.

National Institute of Minority Health and Health Disparities (NIMHD)

The mission of NIMHD is to lead scientific research to improve minority health and reduce health disparities. NIMHD supports novel and innovative research that applies an intersectional lens to examining, addressing, and mitigating the underlying causes, pathways, risks, and inequities adversely impacting the health and well-being of cisgender women and girls, and gender-diverse people among racial and ethnic minority groups and other populations with health disparities.

NIMHD supports science seeking to improve health and reduce HIV-related disparities with a primary focus on racial and ethnic minority women and girls disproportionately affected by HIV, such as gender-diverse people and persons of low socioeconomic status (SES). Black and Latina women account for a combined 72% of women living with HIV, and Black women alone account for 54% of women with new HIV infections. Thus, of interest are novel and innovative research to address the needs of these and other NIH designated populations that experience health disparities, especially using an intersectional lens. Applicants are encouraged to propose topics relevant to the goals outlined in the NIH Strategic Plan on Minority Health and Health Disparities. Studies should also consider multi-level and multidomain influences on minority health and health disparities, as identified in the NIMHD Research Framework. Studies should consider the roles of social determinants of health (SDOH) such as healthcare quality, occupational status, housing stability, or food security and seek to address where possible. NIMHD strongly encourages the use of established SDOH measures from the SDOH Collection of the PhenX Toolkit for more information (www.phenxtoolkit.org).

Topics on HIV prevention, care, and treatment focused on women in NIH-designated populations with health disparities that are of interest to NIMHD include, but are not limited to:

Observational Research

• Examine relationships between intersectionality (e.g., race and ethnicity and sexual orientation) on health outcomes such as viral suppression, ART access and adherence, PrEP awareness and uptake.
• Examine pathways of social and structural determinants leading to disparities in access to care, routine HIV testing, and PrEP access.

Intervention Research

• Develop, test and/or evaluate and evaluate multilevel interventions, within the healthcare system to increase retention in HIV care.
• Test and develop HIV prevention programs addressing specific risk factors, including access to care, poverty, discrimination, exposure to trauma (e.g., interpersonal violence, adverse childhood experiences), substance use, stigma, cultural beliefs, and traditional gender roles.
• Evaluate existing patient, healthcare professional, community, and/or system-level strategies to promote greater uptake of and adherence to treatment in settings that serve high risk women and girls, such as women’s shelters, prisons, mental health and substance use treatment settings.
• Leverage implementation science approaches with community partners to develop effective evidence-based/informed interventions.
• Quality improvement programs to reduce health disparities in areas of HIV testing, treatment (e.g., ART access and adherence, optimal viral load suppression, acute and long-term health complications) and prevention (e.g., PrEP awareness and uptake).
• Develop, test and/or evaluate strategies to coordinate and improve care among women living with HIV and multiple comorbidities co-existing health conditions.
• Test novel data science and analytic methods, including artificial intelligence to improve identification of vulnerabilities, inform end-user data collection in/around women’s preferences/usage of HIV prevention, and treatment modalities across the lifespan.
• Test mhealth interventions to improve HIV care and access and improve quality of life.

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) supports research on the impact of alcohol use on human health and well-being. NIAAA’s high-priority research areas are listed at https://www.niaaa.nih.gov/grants-funding/how-apply-grant/niaaa-statement-research-priorities-and-procedures. Specific areas of interest in research on women’s health and HIV include but are not limited to:

1) Continuums of Care
NIAAA supports multiple approaches to research among girls and women related to patterns of alcohol use and alcohol use disorders relevant to the current announcement focused on HIV/AIDS.  For example, Continuums of Care Initiative (MCCI) to Health Equity and End Health Disparities Among Women and Girls in Racial/Ethnic Minority Communities (see RFA-AA-24-006) is a multi-ICO dissemination and implementation science initiative to advance racial equity and end health disparities in racial/ethnic minority women and girls of reproductive age. This approach is of particular relevance to the current announcement to examine at-risk and women living with HIV/AIDS, and women and girls of reproductive age. Special emphasis is placed on using stakeholder partnerships, provider training, and infrastructure changes to improve access for subgroups of racial/ethnic minority women and girls who currently have the least access to high-quality health care (e.g., racial/ethnic minority women and girls living in low resource settings). Applications that include a partnership between Research Centers in Minority Institutions and other institutions with extensive programs in women's health research are strongly encouraged.

2) Alcohol-exposed pregnancies for women with HIV/AIDS and their children
In addition, a large proportion of pregnant women living with HIV may experience alcohol-exposed pregnancies (over 20%) and this area of research is central to broader NIAAA strategic activities. Research focused on women and girls are centered on ages 15-44 and includes the early reproductive period, i.e., adolescence, when multimorbidity typically begins and rapidly progresses, setting the stage for multiple chronic debilitating conditions in later life. Children and adults prenatally exposed to alcohol may experience lifelong disabilities and a unique combination of day-to-day challenges, which may include medical, behavioral, educational, and social problems. PWH and with FASD (Fetal Alcohol Spectrum Disorders) may have additional difficulty in areas of 1) neurocognition (i.e. global intellectual impairment, executive function deficits, poor working memory, learning problems); 2) self-regulation (i.e. impulse control problems, impaired mood or behavioral regulation, attention deficits, organization difficulties); and 3) adaptive functioning (i.e. communication issues, problems with daily living, poor social skills, gross or fine motor delay). There is a limited understanding of the effects and mechanisms of prenatal exposure to alcohol in pregnant people living with HIV. NIAAA is interested in research to establish an understanding of the relationship between prenatal exposure to alcohol and HIV, mechanisms, and factors that affect pregnancy and maternal and child outcomes and develop multipurpose prevention interventions effective in reducing alcohol use among PHW and improving health outcomes in women living with HIV.

National Institute of Neurological Disorders and Stroke (NINDS)

The NINDS supports basic, translational, and clinical research on the brain and nervous system and uses this knowledge to reduce the burden of neurological disease. In the context of HIV disease, NINDS is particularly interested in the neurological complications of HIV infection that affect the brain, spinal cord, and peripheral nervous system, as well as the ways in which chronic HIV infection of the CNS interacts with and/or potentiates neurological disorders within the mission of NINDS. For this particular NOSI, NINDS encourages basic disease research on sex and gender differences in HIV-associated neurological complications, clinical studies focused on sex- and gender-dependent neurological effects of HIV in people with female sex assigned at birth and women of all backgrounds, and translational studies that propose strategies for the alleviation of HIV-associated neurological co-morbidities in these populations. Studies of the NINDS-relevant HIV topics listed above in all women and people with female sex assigned at birth within populations defined by the NIH to experience health disparities are also of particular interest.

While the NINDS will support studies focused on the effect of chronic HIV on cognitive outcomes in the setting of neurological disease, applications that are solely interested in mental health and psychiatric outcomes will not be supported by the NINDS. This includes applications that solely rely upon RDoC-based constructs for neurobehavioral analyses. Rather, the NINDS strongly prefers the incorporation of additional multidimensional measures of neurological function, such as NIH Toolbox and Neuro-QOL -based assessments of cognitive, motor, and sensory function. In addition, only mechanistic clinical trials and Basic Experimental Studies with Humans (BESH) will be supported by the NINDS under this NOSI. Clinical trials that seek to answer specific questions about safety, tolerability, clinical efficacy, effectiveness, clinical management, and/or implementation of pharmacologic, behavioral, biologic, surgical, or device (invasive or non-invasive) interventions will not be supported. Rather, such projects should be submitted to one of NINDS’ clinical trial-specific funding announcements (such as PAR-22-142 or PAR-21-237). It is strongly encouraged that potential NINDS applicants contact the program officer listed at the bottom of this notice to discuss proposals prior to submission.

NINDS urges investigators to follow the NIH guidance for rigor and transparency in grant applications ( https://grants.nih.gov/policy/reproducibility/guidance.htm ) and additionally recommends the research practices described at  https://www.ninds.nih.gov/Funding/grant_policy to ensure that robust experiments are designed, potential experimenter biases are minimized, results and analyses are transparently reported, and results are interpreted carefully. These recommended research practices include, where applicable: rationale for the chosen model(s) and primary/secondary endpoints, clear descriptions of tools and parameters, blinding, randomization, ensuring adequate sample size, pre-specified inclusion/exclusion criteria, handling of missing data and outliers, appropriate controls, preplanned analyses, appropriate quantitative techniques, clear indication of exploratory vs. confirmatory components of the study, consideration of limitations, and plans for transparent reporting of all methods, analyses, and results so that other investigators can evaluate the quality of the work and potentially perform replications.

National Center for Complementary and Integrative Health (NCCIH)

NCCIH promotes research on the use of complementary and integrative health approaches, which include those that are not typically part of conventional medical care and can be classified by their primary therapeutic input, including nutritional (e.g., botanicals, probiotics and microbial-based therapies, dietary supplements, and special diets), psychological (e.g., meditation, hypnosis, music-based interventions, relaxation therapies), physical (e.g., acupuncture, massage, chiropractic manipulation, other force-based manipulations, or devices related to these approaches), or a combination of psychological and physical input (e.g., yoga, tai chi, dance therapies, or some forms of art therapies). NCCIH's strategic plan is available at https://www.nccih.nih.gov/about/strategic-plans-and-reports. While surveys show the use complementary and integrative therapies is high in women and people living with HIV, the evidence regarding their effectiveness, safety, and underlying mechanisms in cis- and gender-diverse women is often lacking. NCCIH is seeking applications that will establish the mechanistic basis, feasibility, acceptability, and/or efficacy of complementary approaches specifically designed to address the unique complications, comorbidities, and challenges experienced by cis- and gender-diverse women living with HIV, and that can be safely combined with ART to improve physical, mental, and emotional health. NCCIH is also interested in novel research aimed at preventing HIV infection in uninfected, high-risk cis- and gender-diverse women, and interventions that acknowledge and seek to address the intersection of race, ethnicity, social determinants of health, and HIV in women.

Areas of interest to NCCIH include but are not limited to:

• Mind and body (e.g., mindfulness, sleep, force-based manipulation, traditional Chinese medicine, yoga, clinical hypnosis) interventions to reduce HIV-related comorbidities and complications, or reduce the risk of HIV infection among women who are uninfected.
• Trials that evaluate nutritional or natural product therapies, including special diets, botanicals, probiotics, microbial-based therapies, and dietary supplements in women with HIV to reduce or prevent complications or comorbidities
• Complementary and integrative interventions that specifically target women’s gastrointestinal and/or vaginal microbiomes and metabolomes with the aim of reducing the risk of HIV infection among the uninfected, or HIV-related complications and comorbidities in women living with HIV
• Studies to describe and elucidate the mechanisms by which complementary and integrative therapies work in women living with HIV
• Trials that evaluate a standardized nutritional regimen or component to reduce HIV-related comorbidities and complications that predominately occur in women
• Multicomponent interventions, incorporating multiple mind and body and/or natural product therapies, that address HIV-associated complications and comorbidities in women

Investigators are strongly encouraged to discuss their research plans with NCCIH program staff prior to submitting their application, to determine the appropriate NOFO.

For more details on NCCIH’s approach to funding clinical trials, including a description of our available NOFOs, please see https://nccih.nih.gov/grants/funding/clinicaltrials. NCCIH will not support efficacy or effectiveness studies using Parent NOFOs. Applicants should carefully refer to the Consolidated Notice on NCCIH Clinical Trials Policies https://grants.nih.gov/grants/guide/notice-files/NOT-AT-20-001.html, which outlines which Parent Research Project Grants can and cannot be utilized for safety, efficacy/effectiveness, or mechanistic studies. 

Fogarty International Center

The Fogarty International Center (FIC) is interested in research and research career development grant applications proposing studies in Low- and Middle-Income Countries (LMICs) focused on the health of women and girls across the lifespan living with HIV as applicable to research goals outlined in the FIC NOFOs listed in this NOSI.  Globally, women are impacted by gender health gaps, with implications for the well-being of not only themselves but also their families, communities, and societies in general. Some of the gender health gaps may be due to climate change, poverty, cultural and societal norms, gender specific presentation or metabolism of disease processes, and gender-specific conditions such as pregnancy and menopause that affect women in significant ways.  Research projects at the intersection of HIV and women’s health that address topics of relevance to cisgender and transgender women and gender-diverse people to understand basic biomedical, biobehavioral, and social and structural impacts on the health of this population, and development of appropriate culturally relevant interventions to mitigate adverse health outcomes, are also of interest. 

Sexual & Gender Minority Research Office (SGMRO)

The SGMRO develops and coordinates health- and research-related activities for sexual and gender minority (SGM; defined for NIH research in NOT-OD-19-139) populations by working directly with the NIH institutes and centers (ICs) and serves as a liaison for the research community to ensure SGM populations are considered and represented in research activities across the agency. The SGMRO does not have grant-making authority or administer grants. The office can only support grants deemed scientifically meritorious after review by one of the ICs participating in this announcement and after a co-funding request is initiated through the IC. Please reach out to the relevant scientific/research contact(s) identified in this announcement with any questions about IC-specific research priorities and funding. More SGM- and SGMRO-specific information is available in the NIH Strategic Plan to Advance Research on the Health and Well-being of Sexual and Gender Minorities FY 2021-2025, the FY 2021 SGM Research Portfolio Analysis, and on the Office’s Research Resources webpage.

For this NOSI, SGMRO encourages HIV research across the life course (particularly prevention, intervention, and clinical research, but including other types of research as well) to protect, maintain, or improve the health of sexual minority women, transgender men and women, and/or nonbinary and other gender diverse people assigned female at birth. When appropriate, SGMRO encourages consideration and incorporation of relevant concepts (e.g., minority stress, social safety, intersectionality, stigma), research strategies (e.g., community-led or -engaged research, trauma-informed research, strengths-based approaches), and frameworks (e.g., SGM Health Disparities Research Framework, NIMHD Research Framework).

Application and Submission Information

This NOSI applies to due dates on or after June 20, 2024, and subsequent receipt dates through January 7, 2026.

Submit applications for this initiative using one of the following notices of funding opportunity (NOFOs) or any reissues of these announcements through the expiration date of this notice.

Applicants must select the IC and associated NOFO to use for submission of an application in response to this NOSI. Applications must be aligned with one of the mission areas of the selected IC. The selection must align with the IC requirements listed to be considered responsive to that NOFO. Non-responsive applications will be withdrawn from consideration for this initiative. In addition, applicants using NIH Parent Announcements (listed below) will be assigned to those ICs on this NOSI that have indicated those NOFOs are acceptable and based on usual application-IC assignment practices.

All instructions in the SF424 (R&R) Application Guide and the listed funding opportunity announcements must be followed, with the following additions:

• For funding consideration, applicants must include “NOT-OD-24-119” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.

Applications nonresponsive to terms of this NOSI will be withdrawn from consideration for this initiative.

Applications nonresponsive to terms of this NOSI will not be considered for the NOSI initiative.

Inquiries

Please direct all inquiries to the contacts in Section VII of the listed notice of funding opportunity with the following additions/substitutions:

Scientific/Research Contact(s)

Elizabeth Anne Barr, Ph.D.
Office of Research on Women’s Health (ORWH)
Telephone: 301-402-7895
Email: elizabeth.barr@nih.gov

Leslie Marshall, Ph.D. 
Office of AIDS Research (OAR)
Telephone: 301-402-1839
Email: Leslie.marshall@nih.gov

Angela Lee-Winn, PhD
National Institute on Drug Abuse (NIDA)
Telephone: (301) 451-7206
Email: angela.lee-winn@nih.gov

Sekai Chideya-Chihota, MD, MPH
National Center for Complementary and Integrative Health (NCCIH)
Phone: 240-552-2994
Email: sekai.chideya@nih.gov

Sonia Lee, PhD​​​​​​​
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Telephone: 301-594-4783
Email: Sonia.lee@nih.gov

Peter J Perrin, Ph.D.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phone: 301 451-3759
E-mail: peter.perrin@nih.hhs.gov

Ann Namkung, MPH
National Institute on Aging (NIA)
Telephone: 301-496-6838
Email: ann.namkung@nih.gov

Joana Roe
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-627-3213
Email: jroe@niaid.nih.gov

Kristen Porter, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 301-761-7022
Email: kristen.porter@nih.gov

Teri Senn, Ph.D.
National Institute of Mental Health (NIMH)
Telephone: 301-605-4146
Email: teri.senn@nih.gov

Rebecca Liddell Huppi, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-781-3324
Email: liddellr@exchange.nih.gov

Tatiana Balachova, Ph.D.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Telephone: 301-443-5726
Email: Tatiana.Balachova@nih.gov

Deidra Roach, Ph.D.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Telephone:  301-443-5820
Email:  droach@mail.nih.gov

Heiyoung Park, Ph.D.
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Telephone: 301-594-3507
Email: parkh1@mail.nih.gov

William Patrick Daley
NINDS - National Institute of Neurological Disorders and Stroke (NINDS)
Phone: 3014961431
E-mail: william.daley@nih.gov

Geetha Parthasarathy Bansal
FIC - Fogarty International Center
Phone: (301) 496-1653
E-mail: geetha.bansal@nih.gov

Christopher Barnhart, Ph.D.
Sexual & Gender Minority Research Office (SGMRO)
Telephone: 301-594-8983
Email: christopher.barnhart@nih.gov

Yewande A. Oladeinde, PhD 
National Institute on Minority Health & Health Disparities (NIMHD)
Telephone: 301-402-1366
Email: yewande.oladeinde@nih.gov